| Hemophilia A
Hympavzi vs Xyntha
Side-by-side clinical, coverage, and cost comparison for hemophilia a.Deep comparison between: Hympavzi vs Xyntha with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXyntha has a higher rate of injection site reactions vs Hympavzi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xyntha but not Hympavzi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hympavzi
Xyntha
At A Glance
SC injection
Weekly
TFPI antagonist
IV infusion
3 times weekly (prophylaxis)
Factor VIII replacement
Indications
- Hemophilia A
- Hemophilia B
- Hemophilia A
Dosing
Hemophilia A, Hemophilia B Loading dose 300 mg SC (two 150 mg injections); maintenance 150 mg SC once weekly starting one week after loading dose; consider dose adjustment to 300 mg SC weekly in patients >=50 kg with inadequate bleeding control.
Hemophilia A - On-demand / Bleeding episodes Dose calculated as body weight (kg) x desired FVIII rise (IU/dL) x 0.5; minor bleeds: 20-40 IU/dL target every 12-24 hrs; moderate: 30-60 IU/dL every 12-24 hrs; major: 60-100 IU/dL every 8-24 hrs; IV infusion.
Hemophilia A - Perioperative management Minor surgery: 30-60 IU/dL target every 12-24 hrs for 3-4 days; major surgery: 60-100 IU/dL target every 8-24 hrs until adequate local hemostasis achieved; IV infusion.
Hemophilia A - Routine prophylaxis Adults and adolescents (>=12 years): 30 IU/kg 3 times weekly IV; adjust dose or frequency based on clinical response.
Contraindications
—
- Life-threatening immediate hypersensitivity reactions, including anaphylaxis, to XYNTHA or its components, including hamster proteins
Adverse Reactions
Most common (>=3%) Injection site reaction, headache, pruritus
Serious Thromboembolic events, hypersensitivity, peripheral swelling, venous thrombosis
Most common (>=10%) Headache, arthralgia, pyrexia, cough
Postmarketing Inadequate therapeutic response
Pharmacology
Marstacimab-hncq is a human monoclonal IgG1 antibody that targets the Kunitz domain 2 (K2) of tissue factor pathway inhibitor (TFPI), neutralizing TFPI activity and enhancing thrombin generation via the extrinsic coagulation pathway.
XYNTHA temporarily replaces missing clotting factor VIII needed for effective hemostasis; treatment normalizes activated partial thromboplastin time (aPTT) over the effective dosing period.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hympavzi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Xyntha
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Hympavzi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (3/8)
Xyntha
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Hympavzi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Xyntha
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited and Acquired Factor Deficiencies - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HympavziView full Hympavzi profile
XynthaView full Xyntha profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.